|1.||Amer, J: 1 article (07/2009)|
|2.||Safadi, R: 1 article (07/2009)|
|3.||Doron, S: 1 article (07/2009)|
|4.||Muhanna, N: 1 article (07/2009)|
|5.||Koren, E: 1 article (07/2009)|
|6.||Mahamid, M: 1 article (07/2009)|
|7.||Horani, A: 1 article (07/2009)|
|8.||Ginsburg, I: 1 article (07/2009)|
07/01/2009 - "In this study, we evaluate the immune efficacy of Padma Hepaten administered intraperitoneally (i.p.) and/or orally in a mice model of hepatic fibrosis. "
07/01/2009 - "Adoptive transfer of Padma Hepaten-treated lymphocytes was associated with fibrosis amelioration compared with recipients with naive lymphocytes. "
07/01/2009 - "There were four groups, including naive mice, non-treated fibrotic mice and fibrotic mice treated by Padma Hepaten at weeks 5-6 of fibrosis induction either orally or by i.p. "
07/01/2009 - "Amelioration of hepatic fibrosis via Padma Hepaten is associated with altered natural killer T lymphocytes."
07/01/2009 - "Hepatic fibrosis and alanine aminotransferase serum levels were decreased significantly in both Padma Hepaten-treated groups compared with the non-treated fibrotic group. "
|1.||Alanine Transaminase (SGPT)